Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 Mpro mutants and MERS-CoV Mpro

25 Mar 2025

Abstract excerpt

The COVID-19 pandemic has caused significant global health and economic disruption. Mutations E166N, E166R, E166N, S144A and His163A in the SARS-CoV-2 main protease (Mpro) have been implicated in reducing the efficacy of certain antiviral treatments. Bofutrelvir, a promising inhibitor, has shown effectiveness against SARS-CoV-2 Mpro. This study aims to evaluate the inhibitory effects of Bofutrelvir on the E166N,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40133408
DOI: 10.1038/s42003-025-07929-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 Mpro mutants and MERS-CoV MproPMID 40133408Read ↗

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity Read ↗

Structural basis for varying drug resistance of SARS-CoV-2 Mpro E166 variants.Semantic proximity Read ↗

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 VariantsSemantic proximity Read ↗

In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease.Semantic proximity Read ↗

Mechanistic Insights into the Mutational Landscape of the Main Protease/3CLPro and Its Impact on Long-Term COVID-19/SARS-CoV-2 ManagementSemantic proximity Read ↗

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variantsSemantic proximity Read ↗

SARS-CoV-2 main protease (M-pro) mutational profiling: An insight into mutation coldspots.Semantic proximity Read ↗

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Semantic proximity Read ↗

Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid.Semantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231Semantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231.Semantic proximity Read ↗

Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.